Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer

Yukio Hosomi; Masahiko Shibuya; Seiji Niho; Yukito Ichinose; Katsuyuki Kiura; Hiroshi Sakai; Koji Takeda; Shinzo Kudo; Kenji Eguchi; Kaoru Matsui; Noriyuki Masuda; Masahiro Ando; Koshiro Watanabe

Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer

Yukio Hosomi, Masahiko Shibuya, Seiji Niho, Yukito Ichinose, Katsuyuki Kiura, Hiroshi Sakai, Koji Takeda, Shinzo Kudo, Kenji Eguchi, Kaoru Matsui, Noriyuki Masuda, Masahiro Ando, Koshiro Watanabe

University Hospital

Research output: Contribution to journal › Article

8 Citations (Scopus)

Abstract

Background: We conducted a phase II study of topotecan (Tp) with cisplatin (CDDP) in previously untreated Japanese patients with extensive-disease small cell lung cancer (ED-SCLC). Patients and Methods: In stage 1, a total of 30 patients were allocated to Tp 0.65 mg/m ² with CDDP 60 mg/m ² day 1 or Tp 1.00 mg/m ² with CDDP day 5 following prophylactic granulocyte colony stimulating factor (G-CSF) from day 6. In stage 2, the selective combination in 29 patients was evaluated for response rate, toxicity and overall survival. Results: In stage 1, Tp 1.00 mg/m ² with CDDP day 5 was selected this schedule had a better hematological profile. In stage 2, the response rate was 83%, and grade 3/4 adverse events were hematological-toxicities. The median survival time was 17.5 months and the 1 year survival rate was 79%. Conclusion: Combination of Tp and CDDP on day 5 with G-CSF support is safe and effective for previously untreated ED-SCLC Japanese patients.

Original language	English
Pages (from-to)	3449-3456
Number of pages	8
Journal	Anticancer research
Volume	31
Issue number	10
Publication status	Published - Oct 1 2011

Keywords

Cisplatin
Small cell lung cancer
Topotecan

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

Fingerprint Dive into the research topics of 'Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer'. Together they form a unique fingerprint.

Cite this

Hosomi, Y., Shibuya, M., Niho, S., Ichinose, Y., Kiura, K., Sakai, H., Takeda, K., Kudo, S., Eguchi, K., Matsui, K., Masuda, N., Ando, M., & Watanabe, K. (2011). Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. Anticancer research, 31(10), 3449-3456.

Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. / Hosomi, Yukio; Shibuya, Masahiko; Niho, Seiji; Ichinose, Yukito; Kiura, Katsuyuki; Sakai, Hiroshi; Takeda, Koji; Kudo, Shinzo; Eguchi, Kenji; Matsui, Kaoru; Masuda, Noriyuki; Ando, Masahiro; Watanabe, Koshiro.

In: Anticancer research, Vol. 31, No. 10, 01.10.2011, p. 3449-3456.

Research output: Contribution to journal › Article

Hosomi, Yukio ; Shibuya, Masahiko ; Niho, Seiji ; Ichinose, Yukito ; Kiura, Katsuyuki ; Sakai, Hiroshi ; Takeda, Koji ; Kudo, Shinzo ; Eguchi, Kenji ; Matsui, Kaoru ; Masuda, Noriyuki ; Ando, Masahiro ; Watanabe, Koshiro. / Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer. In: Anticancer research. 2011 ; Vol. 31, No. 10. pp. 3449-3456.

@article{b9b49177e9434bb9bb94faf7f932f977,

title = "Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer",

abstract = "Background: We conducted a phase II study of topotecan (Tp) with cisplatin (CDDP) in previously untreated Japanese patients with extensive-disease small cell lung cancer (ED-SCLC). Patients and Methods: In stage 1, a total of 30 patients were allocated to Tp 0.65 mg/m 2 with CDDP 60 mg/m 2 day 1 or Tp 1.00 mg/m 2 with CDDP day 5 following prophylactic granulocyte colony stimulating factor (G-CSF) from day 6. In stage 2, the selective combination in 29 patients was evaluated for response rate, toxicity and overall survival. Results: In stage 1, Tp 1.00 mg/m 2 with CDDP day 5 was selected this schedule had a better hematological profile. In stage 2, the response rate was 83%, and grade 3/4 adverse events were hematological-toxicities. The median survival time was 17.5 months and the 1 year survival rate was 79%. Conclusion: Combination of Tp and CDDP on day 5 with G-CSF support is safe and effective for previously untreated ED-SCLC Japanese patients.",

keywords = "Cisplatin, Small cell lung cancer, Topotecan",

author = "Yukio Hosomi and Masahiko Shibuya and Seiji Niho and Yukito Ichinose and Katsuyuki Kiura and Hiroshi Sakai and Koji Takeda and Shinzo Kudo and Kenji Eguchi and Kaoru Matsui and Noriyuki Masuda and Masahiro Ando and Koshiro Watanabe",

year = "2011",

month = oct,

day = "1",

language = "English",

volume = "31",

pages = "3449--3456",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "10",

}

TY - JOUR

T1 - Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer

AU - Hosomi, Yukio

AU - Shibuya, Masahiko

AU - Niho, Seiji

AU - Ichinose, Yukito

AU - Kiura, Katsuyuki

AU - Sakai, Hiroshi

AU - Takeda, Koji

AU - Kudo, Shinzo

AU - Eguchi, Kenji

AU - Matsui, Kaoru

AU - Masuda, Noriyuki

AU - Ando, Masahiro

AU - Watanabe, Koshiro

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Background: We conducted a phase II study of topotecan (Tp) with cisplatin (CDDP) in previously untreated Japanese patients with extensive-disease small cell lung cancer (ED-SCLC). Patients and Methods: In stage 1, a total of 30 patients were allocated to Tp 0.65 mg/m 2 with CDDP 60 mg/m 2 day 1 or Tp 1.00 mg/m 2 with CDDP day 5 following prophylactic granulocyte colony stimulating factor (G-CSF) from day 6. In stage 2, the selective combination in 29 patients was evaluated for response rate, toxicity and overall survival. Results: In stage 1, Tp 1.00 mg/m 2 with CDDP day 5 was selected this schedule had a better hematological profile. In stage 2, the response rate was 83%, and grade 3/4 adverse events were hematological-toxicities. The median survival time was 17.5 months and the 1 year survival rate was 79%. Conclusion: Combination of Tp and CDDP on day 5 with G-CSF support is safe and effective for previously untreated ED-SCLC Japanese patients.

AB - Background: We conducted a phase II study of topotecan (Tp) with cisplatin (CDDP) in previously untreated Japanese patients with extensive-disease small cell lung cancer (ED-SCLC). Patients and Methods: In stage 1, a total of 30 patients were allocated to Tp 0.65 mg/m 2 with CDDP 60 mg/m 2 day 1 or Tp 1.00 mg/m 2 with CDDP day 5 following prophylactic granulocyte colony stimulating factor (G-CSF) from day 6. In stage 2, the selective combination in 29 patients was evaluated for response rate, toxicity and overall survival. Results: In stage 1, Tp 1.00 mg/m 2 with CDDP day 5 was selected this schedule had a better hematological profile. In stage 2, the response rate was 83%, and grade 3/4 adverse events were hematological-toxicities. The median survival time was 17.5 months and the 1 year survival rate was 79%. Conclusion: Combination of Tp and CDDP on day 5 with G-CSF support is safe and effective for previously untreated ED-SCLC Japanese patients.

KW - Cisplatin

KW - Small cell lung cancer

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=80054741764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054741764&partnerID=8YFLogxK

M3 - Article

C2 - 21965760

AN - SCOPUS:80054741764

VL - 31

SP - 3449

EP - 3456

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 10

ER -